{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104963",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104963",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for capecitabine and DPYD",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA448771",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA448771",
    "name" : "capecitabine"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA145",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA145",
    "symbol" : "DPYD",
    "name" : "dihydropyrimidine dehydrogenase"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>Select an alternate drug to capecitabine for DPYD poor metabolizer patients, and reduce capecitabine dose (by 50%) or select an alternate drug for DPYD intermediate metabolizers.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for capecitabine (a fluorouracil prodrug) based on DPYD genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend that an alternate drug be used for poor metabolizer patients, and a reduced dose or alternate drug for intermediate metabolizer patients.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> PM (2 inactive alleles, 2 decreased activity alleles, or one inactive and one decreased activity alleles) </td><td> Select alterantive drug.  Tegafur is not a suitable alternative because this drug is also metabolized by DPD. </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression. </td></tr><tr><td> IM (1 active allele and 1 inactive or decreased activity allele) </td><td> Reduce dose by 50% or select alternative drug.  Tegafur is not a suitable alternative because this drug is also a substrate for DPD.  Increase dose in response to toxicity and efficacy.  </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression. </td></tr></table><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Allele Type </th><th> Alleles </th></tr><tr><td> active </td><td> *1, *4, *5, *6, *9A </td></tr><tr><td> decreased activity </td><td> *9B, *10 </td></tr><tr><td> inactive </td><td> *2A, *3, *7, *8, *11, *12, *13, 496A&gt;G, IVS10-15T&gt;C, 1156G&gt;T, 1845G&gt;T </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li><li>S: statistically significant difference.</li></ul>"
}